Long non-coding RNAs in anti-cancer drug resistance

Qin-nan Chen; Chen-chen Wei; Zhao-xia Wang; Ming Sun

doi:10.18632/oncotarget.12461

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Long non-coding RNAs in anti-cancer drug resistance

Qin-nan Chen, Chen-chen Wei, Zhao-xia Wang _ and Ming Sun

PDF | HTML | How to cite

Oncotarget. 2017; 8:1925-1936. https://doi.org/10.18632/oncotarget.12461

Metrics: PDF 5243 views | HTML 5547 views | ?

Abstract

Qin-nan Chen1, Chen-chen Wei1, Zhao-xia Wang1 and Ming Sun2

1 Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, People’s Republic of China

2 Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston, Texas, United States of America

Correspondence to:

Zhao-Xia Wang, email:

Ming Sun, email:

Keywords: long non-coding RNAs, cancer, drug resistance, chemotherapy, targets

Received: May 29, 2016 Accepted: September 16, 2016 Published: October 04, 2016

Abstract

Chemotherapy is one of the basic treatments for cancers; however, drug resistance is mainly responsible for the failure of clinical treatment. The mechanism of drug resistance is complicated because of interaction among various factors including drug efflux, DNA damage repair, apoptosis and targets mutation. Long non-coding RNAs (lncRNAs) have been a focus of research in the field of bioscience, and the latest studies have revealed that lncRNAs play essential roles in drug resistance in breast cancer, gastric cancer and lung cancer, et al. Dysregulation of multiple targets and pathways by lncRNAs results in the occurrence of chemoresistance. In this review, we will discuss the mechanisms underlying lncRNA-mediated resistance to chemotherapy and the therapeutic potential of lncRNAs in future cancer treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12461

Publication Alerts

Reviews:

Long non-coding RNAs in anti-cancer drug resistance

Abstract